Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab

Neuro-Oncology

Volumn 13, Issue 6, 2011, Pages 660-668

  Wefel, Jeffrey S ^a   Cloughesy, Timothy ^b   Zazzali, James L ^c   Zheng, Maoxia ^c   Prados, Michael ^d   Wen, Patrick Y ^e   Mikkelsen, Tom ^f   Schiff, David ^g   Abrey, Lauren E ^h   Alfred Yung, W K ^a   Paleologos, Nina ⁱ   Nicholas, Martin K ^j   Jensen, Randy ^k   Vredenburgh, James ^l   Das, Asha ^c   Friedman, Henry S ^l  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g UNIVERSITY OF VIRGINIA   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k UNIVERSITY OF UTAH   (United States)

^l DUKE CANCER INSTITUTE   (United States)

more..

Author keywords

Bevacizumab; Cognitive function; Glioblastoma; Quality of life

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; CORTICOSTEROID; IRINOTECAN; OPIATE; PSYCHOSTIMULANT AGENT;

ADULT; ARTICLE; CANCER PATIENT; COGNITION; CONTROLLED ORAL WORD ASSOCIATION; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HOPKINS VERBAL LEARNING TEST REVISED; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MULTICENTER STUDY; NERVOUS SYSTEM FUNCTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUOMOTOR COORDINATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; COGNITION; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959947030     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor024     Document Type: Article

References (30)

1. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol. 2000;18:646-650. (Pubitemid 30078546)
2. Giovagnoli AR, Silvani A, Colombo E, Boiardi A. Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry. 2005;76:562-568. (Pubitemid 40486584)
3. Farace E, Shaffrey ME. Relationship of neurocognitive impairment to QOL in malignant brain tumor patients. Society for Neuro-Oncology Fifth Annual Meeting: November 9-12, 2000, Chicago, IL; Abstract 61, 2000.
4. Meyers CA, Boake C. Neurobehavioral disorders experienced by brain tumor patients: Rehabilitation strategies. Cancer Bull. 1993;45:362-364. (Pubitemid 23262154)
5. Tomaszewski FS, Cahn-Weiner DA, Harvey DJ, et al. Longitudinal changes in memory and executive functioning are associated with longitudinal change in instrumental activities of daily living in older adults. The Clinical Neuropsychologist. 2008;23:446-461.
6. Li J, Bentzen SM, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys. 2008;71:64-70. (Pubitemid 351506468)
7. Brown PD, Jensen AW, Felten SJ. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol. 2006;24:5427-5433. (Pubitemid 46623176)
8. Bosma I, Vos MJ, Heimans JJ, et al. The course of neurocognitive functioning in high-grade glioma patients. Neuro Oncol. 2007;9:53-62. (Pubitemid 46543489)
9. Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol. 2003;5:89-95. (Pubitemid 36416837)
10. Armstrong CL, Goldstein B, Shera D, Ledakis GE, Tallent EM. The predictive value of longitudinal neuropsychologic assessment in the early detection of brain tumor recurrence. Cancer. 2003;97:649-656. (Pubitemid 36125842)
11. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
12. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
14. Macdonald DR, Cascino TL, Schold SC, Jr, Calmcross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280. (Pubitemid 20195640)
15. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. The Clinical Neuropsychologist. 1998;12:43-55. (Pubitemid 28168220)
16. Heaton RK, Miller SW, Taylor MJ, et al. Revised comprehensive norms for an expanded Halstead-Reitan battery. Odessa, FL: PAR, 2004.
17. Ruff RM, Light RH, Parker SB, Levin HS. Benton Controlled Oral Word Association Test: reliability and updated norms. Arch Clin Neuropsychol. 1996;11:329-338. (Pubitemid 26171060)
18. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59:12-19.
19. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22:157-165. (Pubitemid 41095128)
20. Benedict RH, Zgaljardic DJ. Practice effects during repeated administrations of memory tests with and without alternate forms. J Clin Exp Neuropsychol. 1998;20:339-352. (Pubitemid 28539554)
21. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009;27:2905-2908.
22. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol. 2006;24:1305-1309. (Pubitemid 46622034)
23. Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery. 2000;47:324-333, discussion 333-334. (Pubitemid 32049338)
24. Klein M, Postma TJ, Taphoorn MJ, et al. The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology. 2003;61:1796-1798. (Pubitemid 38020834)
25. Levin VA, Yung WK, Bruner J, et al. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys. 2002;53:58-66. (Pubitemid 34465808)
26. Meyers CA, Kudelka AP, Conrad CA, et al. Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res. 1997;3:419-422. (Pubitemid 27158066)
27. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003;21:3557-3558. (Pubitemid 46594045)
28. Reitan RM. Trail Making Test: Manual for administration and scoring. Tucson, AZ: Reitan Neuropsychology Laboratory, 1992, 1958.
29. Levine AJ, Miller EN, Becker JT, Selnes OA, Cohen BA. Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. Clin Neuropsychol. 2004;18:373-384. (Pubitemid 39577274)
30. Benton AL, Hamsher KDS. Multilingual aphasia examination. Iowa City: AJA Associates; 1989.